Thane Wettig

CEO Thane Wettig bought 2,800 shares of KYNB at $7.09 on 2026-05-14; cross-ticker track record shows 100% win rate with avg 90d return +760.6%

Thane Wettig, CEO of Kyntra Bio, purchased 2,800 shares at $7.09, increasing his holdings by 11.5% to 27,203 shares. The transaction occurs in a context of significant business deterioration: annual revenue has contracted 78.3% and the company posted a net loss of $-15,198,000.00 against quarterly revenue of $3,738,000.00, indicating severe operational challenges. Notably, Wettig's cross-ticker track record across open-market buys shows a 100% win rate with an average 90-day return of +760.6%, though these prior outcomes span multiple tickers and may not predict results at Kyntra Bio. The current stock price of $7.13 remains 26.5% below the 52-week high, and recent momentum is modest (30-day change +1.9%, 90-day change +2.3%), presenting a material gap between the executive's demonstrated historical execution across other positions and the deteriorating fundamentals visible here.

CEO Thane Wettig bought 3,700 shares at avg $9.12 across 2 buys; stock at $8.70, down 55.0% from 52-week high.

Wettig Thane, CEO of FGEN, executed 2 separate open-market purchases totaling 3,700 shares for $33,749.73, expanding his stake by 17.4% to 24,939 shares. The blended average price of $9.12 contrasts sharply with the current price of $8.70 and the 52-week high of $19.31—the stock has declined 55.0% from its peak and 16.2% over the prior 30 days, situating this buy near recent lows. Notably, Wettig's prior two buys at FGEN (2025-03-24 and 2024-03-07) each posted strong 90-day returns of +2093.0% and +2021.1%, demonstrating a consistent pattern of well-timed accumulation at this ticker. However, underlying fundamentals are deeply troubled: annual revenue growth stands at -80.0%, quarterly revenue is just $1.1M, and the company posted a full-year net loss despite reporting $200.6M current-quarter net income (likely a restatement or one-time item that masks broader negative operations). The 0.16 P/E and $35.2M market cap reflect severe distress. This purchase by the CEO during a steep drawdown warrants examination of whether Wettig is accumulating at a capitulation point or responding to material developments not yet public.

FGEN CEO Wettig Thane bought 145,000 shares at $0.35 on 2025-03-24 (total $50.7K), increasing holdings 36.4% to 543.3K shares amid -87.0% decline from 52-week high.

CEO Wettig Thane purchased 145,000 shares at $0.35, the lowest price point in the company's 52-week trading range of $7.47–$66.00, representing a rare point of extreme distress given the stock's -87.0% decline from its 52-week peak and -51.5% drop over the past 30 days. This purchase occurred against a backdrop of severe operational deterioration: annual revenue declined -80.0%, the company posted a net loss of $17.1M on quarterly revenue of $46.3M, and remains unprofitable on a full-year basis. The CEO's prior buy at this same ticker on 2024-03-07 produced a +2021.1% 30-day return and +1484.3% 90-day return, establishing a pattern of well-timed accumulation at FGEN, yet the current environment presents markedly different risk: the company's collapsing revenue base and deepening losses create structural uncertainty about whether historically favorable recovery dynamics will repeat. The 36.4% increase in the CEO's holdings signals material conviction, but the deteriorating operational fundamentals merit investor scrutiny of the company's pathway to stabilization.